R-Flurbiprofen reverses multidrug resistance, proliferation and metastasis in gastric cancer cells by p75 NTR induction

Molecular Pharmaceutics

Volumn 7, Issue 1, 2010, Pages 156-168

  Jin, Haifeng ^a   Wang, Zhipeng ^b   Liu, Lili ^a   Gao, Liucun ^a   Sun, Li ^a   Li, Xiaohua ^a   Zhao, Hongxi ^c   Pan, Yanglin ^a   Shi, Hai ^a   Liu, Na ^b   Hong, Liu ^b   Liang, Jie ^b   Wu, Qiong ^b   Yang, Zhiping ^b   Wu, Kaichun ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; P75; R flurbiprofen

Indexed keywords

ACETYLSALICYLIC ACID; CASPASE 3; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLOOXYGENASE 2; DOXORUBICIN; FLUOROURACIL; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOMYCIN; NEUROTROPHIN RECEPTOR P75; PROTEIN BCL 2; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; METASTASIS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR VOLUME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; FLURBIPROFEN; HUMANS; MICE; MICE, NUDE; NERVE TISSUE PROTEINS; RECEPTORS, NERVE GROWTH FACTOR; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76249117703     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900189x     Document Type: Article

References (38)

1. Hung, W. C. Anti-metastatic action of non-steroidal anti-inflammatory drugs. Kaohsiung J. Med. Sci. 2008, 24, 392-7.
2. Kang, H. K.; Lee, E.; Pyo, H.; Lim, S. J. Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol. Cancer Ther. 2005, 4, 1358-63.
3. Wechter, W. J.; Kantoci, D.; Murray, E. D.; Quiggle, D. D.; Leipold, D. D.; Gibson, K. M.; McCracken, J. D. R-Flurbiprofen chemoprevention and treatment of intestinal adenomas in the APCMin/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res. 1997, 57, 4316-24.
4. Wechter, W. J.; Leipold, D. D.; Murray, E. D.; Quiggle, D.; McCracken, J. D.; Barrios, R. S.; Greenberg, N. M. E-7869 (R-Flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res. 2000, 60, 2203-8.
5. Wechter, W. J.; Murray, E. D.; Kantoci, D.; Quiggle, D. D.; Leipold, D. D.; Gibson, K. M.; McCracken, J. D. Treatment and survival study in the C57BL/6J-APCMin/+ (MIN) Mouse with R-Flurbiprofen. Life Sci. 2000, 66, 745-53.
6. Grösch, S.; Tegeder, I.; Schilling, K.; Maier, T.; Niederberger, E.; Geisslinger, G. Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers. FASEB J. 2003, 17, 1316-8.
7. Quann, E. J.; Khwaja, F.; Zavitz, K. H.; Djakiew, D. The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007, 67, 3254-62.
8. Fantappie, O.; Solazzo, M.; Lasagna, N.; Platini, F.; Tessitore, L.; Mazzanti, R. P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res. 2007, 67, 4915-23.
9. Liu, X. G.; Yue, P.; Zhou, Z. M.; Khuri, F. R.; Sun, S. Y. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J. Natl. Cancer Inst. 2004, 96, 1769-80.
10. Ko, S. H.; Choi, G. J.; Lee, J. H.; Han, Y. A.; Lim, S. J.; Kim, S. H. Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma. Oncol. Rep. 2008, 19, 425-33.
11. Abiru, S. Aspirin and NS-398 inhibit hepatocyte growth factorinduced invasiveness of human hepatoma cells. Hepatology 2002, 35, 1117-24.
12. Pan, M. R.; Hung, W. C. Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. J. Biol. Chem. 2002, 277, 32775-80.
13. Abdelrahim, M.; Baker, C. H.; Abbruzzese, J. L.; Safe, S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J. Natl. Cancer Inst. 2006, 98, 855-68.
14. Song, J. H.; Kim, S. H.; Kim, H. J.; Hwang, S. Y.; Kim, T. S. Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin. Int. J. Oncol. 2008, 32, 931-6.
15. Pan, M. R.; Chang, H. C.; Hung, W. C. Non-steroidal antiinflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases. Cell. Signalling 2008, 20, 1134-41.
16. Quann, E. J.; Khwaja, F.; Djakiew, D. The p38 MAPK pathway mediates Aryl propionic acid-induced messenger RNA stability of p75NTR in prostate cancer cells. Cancer Res. 2007, 67, 11402-10.
17. Khwaja, F. S.; Quann, E. J.; Pattabiraman, N.; Wynne, S.; Djakiew, D. Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Mol. Cancer Ther. 2008, 7, 3539-45.
18. Andrews, P.; Zhao, X.; Allen, J.; Li, F.; Chang, M. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother. Pharmacol. 2008, 61, 203-14.
19. Khwaja, F.; Allen, J.; Lynch, J.; Andrews, P.; l Djakiew, D. Ibuprofen inhibits survival of bladder cancer cells by induced expression of the p75NTR tumor suppressor protein. Cancer Res. 2004, 64, 6207-13.
20. Jin, H. F. p75 neurotrophin receptor suppresses the proliferation of human gastric cancer cells. Neoplasia 2007, 9, 471-8.
21. Jin, H. F. p75 neurotrophin receptor inhibits invasion and metastasis of gastric cancer. Mol. Cancer Res. 2007, 5, 423-33.
22. Leung, W. K.; Sung, J. J. Chemoprevention of gastric cancer. Eur. J. Gastroenterol. Hepatol. 2006, 18, 867-71.
23. Ristimäki, A.; Honkanen, N.; Jänkälä, H.; Sipponen, P.; Härkönen, M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997, 57, 1276-80.
24. Uefuji, K.; Ichikura, T.; Mochizuki, H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin. Cancer Res. 2000, 6, 135-8.
25. Huang, L. B.; Wang, C. H.; Zheng, W. B.; Liu, R.; Yang, J. L.; Tang, C. W. Effects of celecoxib on the reversal of multidrug resistance in human gastric carcinoma by downregulation of the expression and activity of P-glycoprotein. Anti-Cancer Drugs 2007, 18, 1075-80.
26. Li, S.; Shi, Y.; Guo, C.; Yao, L.; Lin, T.; Du, J.; Han, Q.; Han, Y.; Fan, D. Regulation of multidrug resistance by MGr1-antigen in gastric cancer cells. Tumor Biol. 2005, 827, 1-9.
27. Du, J.; Pan, Y.; Shi, Y.; Guo, C.; Jin, X.; Sun, L.; Liu, N.; Qiao, T.; Fan, D. Overexpression and significance of prion protein in gastric cancer and multidrug-resistant gastric carcinoma cell line SGC7901/ADR. Int. J. Cancer 2005, 113, 213-20.
28. Yamaue, H.; Tanimura, H.; Noguchi, K.; Hotta, T.; Tani, M.; Tsunoda, T.; Iwahashi, M.; Tamai, M.; Iwakura, S. Chemosensitivity testing of fresh human gastric cancer with highly purified tumor cells using the MTT assay. Br. J. Cancer 1992, 66, 794-9.
29. Yamaue, H.; Tani, M.; Onishi, H.; Kinoshita, H.; Nakamori, M.; Yokoyama, S.; Iwahashi, M.; Uchiyama, K. Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas 2002, 25, 366-72.
30. Lin, W.; Zhang, J.; Zhang, J.; Liu, X.; Fei, Z.; Li, X.; Davidovic, L.; Tang, Z.; Shen, L.; Deng, Y.; Yang, A.; Han, H.; Zhang, X.; Yao, L. RNAi-mediated inhibition of MSP58 decreases tumor growth, migration and invasion in a human glioma cell line. J. Cell Mol. Med. 2008, 15. [Epub ahead of print].
31. Pan, Y.; Bi, F.; Liu, N.; Xue, Y.; Yao, X.; Zheng, Y.; Fan, D. Expression of seven main Rho family members in gastric carcinoma. Biochem. Biophys. Res. Commun. 2004, 315, 686-91.
32. Chi, X.; Freeman, B. M.; Tong, M.; Zhao, Y.; Tai, H. H. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. Arch. Biochem. Biophys. 2009, 487, 139-45.
33. Peng, C. H.; Huang, C. N.; Hsu, S. P.; Wang, C. J. Penta-acetyl geniposide-induced apoptosis involving transcription of NGF/p75 via MAPK-mediated AP-1 activation in C6 glioma cells. Toxicology 2007, 238, 130-9.
34. Gottesman, M. M.; Ling, V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 2006, 580, 998-1009.
35. Guo, X.; Ma, N.; Wang, J.; Song, J.; Bu, X.; Cheng, Y.; Sun, K.; Xiong, H.; Jiang, G.; Zhang, B.; Wu, M.; Wei, L. Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 2008, 8, 375.
36. Zatelli, M. C.; Luchin, A.; Piccin, D.; Tagliati, F.; Bottoni, A.; Vignali, C.; Bondanelli, M.; degli Uberti, E. C. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J. Clin. Endocrinol. Metab. 2005, 90, 5754-60.
37. El-Sheikh, A. K.; van den Heuvel, J. J. M. W.; Koenderink, J. B.; Russel, F. G. M. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J. Pharmacol. Exp. Ther. 2007, 320, 229-35.
38. Wijngaarden, J.; Beek, E.; Rossum, G.; Bent, C.; Hoekman, K.; Pluijm, G.; Pol, M. A.; Broxterman, H. J.; Hinsbergh, V. W.; Löwik, C. W. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kB-mediated increase of intracellular doxorubicin accumulation. Eur. J. Cancer 2007, 43, 433-42.